Nocturia improvement in the combination of Avodart<sup>®</sup> and tamsulosin (CombAT) study

Matthias Oelke, Claus Roehrborn, Carlos D’Ancona, Timothy H. Wilson, Ramiro Castro, Michael Manyak

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: The purpose of the study was to assess the impact of dutasteride plus tamsulosin combination therapy, compared with dutasteride or tamsulosin monotherapy, on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) using data from the 4-year CombAT study.

Methods: Nocturia was assessed using Question 7 of the International Prostate Symptom Score questionnaire. Efficacy measures included as follows: mean change in nocturia at 3-month intervals up to 48 months; proportion of patients with improvement/worsening in nocturia; nocturnal voiding frequency at baseline and study end, overall and by baseline subgroups; and nocturnal voiding frequency <2 at study end in patients with a baseline score ≥2.

Conclusions: Combination therapy provided greater improvements and less worsening of nocturia compared with both dutasteride and tamsulosin monotherapies. These analyses are the first to show greater improvement with a 5ARI/α-blocker combination versus either agent alone for the management of nocturia in patients with LUTS/BPH.

Results: In total, 4,722 patients with a mean age of 66 years were included. Mean nocturia improvements were significantly superior (p ≤ 0.01) with combination therapy than with either monotherapy (adjusted mean change from baseline in IPSS Question 7 score at month 48: combination therapy −0.5, dutasteride −0.4, tamsulosin −0.3). Reduction in nocturia score with combination therapy was significantly (p ≤ 0.01) better than tamsulosin monotherapy across all baseline subgroups tested, except for men with previous 5ARI use. Among those with a baseline IPSS Q7 score ≥2, more patients with combination therapy had a score <2 at month 48 (34 %) compared with dutasteride (30 %, p = 0.018) or tamsulosin (26 %, p < 0.0001).

Original languageEnglish (US)
Pages (from-to)1133-1140
Number of pages8
JournalWorld Journal of Urology
Volume32
Issue number5
DOIs
StatePublished - 2014

Fingerprint

tamsulosin
Nocturia
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Therapeutics
Dutasteride

Keywords

  • Combination drug therapy
  • Dutasteride
  • Nocturia
  • Randomised controlled trial
  • Tamsulosin

ASJC Scopus subject areas

  • Urology

Cite this

Nocturia improvement in the combination of Avodart<sup>®</sup> and tamsulosin (CombAT) study. / Oelke, Matthias; Roehrborn, Claus; D’Ancona, Carlos; Wilson, Timothy H.; Castro, Ramiro; Manyak, Michael.

In: World Journal of Urology, Vol. 32, No. 5, 2014, p. 1133-1140.

Research output: Contribution to journalArticle

Oelke, Matthias ; Roehrborn, Claus ; D’Ancona, Carlos ; Wilson, Timothy H. ; Castro, Ramiro ; Manyak, Michael. / Nocturia improvement in the combination of Avodart<sup>®</sup> and tamsulosin (CombAT) study. In: World Journal of Urology. 2014 ; Vol. 32, No. 5. pp. 1133-1140.
@article{e7eabd1d268f4a03a603067693afcf92,
title = "Nocturia improvement in the combination of Avodart{\circledR} and tamsulosin (CombAT) study",
abstract = "Purpose: The purpose of the study was to assess the impact of dutasteride plus tamsulosin combination therapy, compared with dutasteride or tamsulosin monotherapy, on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) using data from the 4-year CombAT study.Methods: Nocturia was assessed using Question 7 of the International Prostate Symptom Score questionnaire. Efficacy measures included as follows: mean change in nocturia at 3-month intervals up to 48 months; proportion of patients with improvement/worsening in nocturia; nocturnal voiding frequency at baseline and study end, overall and by baseline subgroups; and nocturnal voiding frequency <2 at study end in patients with a baseline score ≥2.Conclusions: Combination therapy provided greater improvements and less worsening of nocturia compared with both dutasteride and tamsulosin monotherapies. These analyses are the first to show greater improvement with a 5ARI/α-blocker combination versus either agent alone for the management of nocturia in patients with LUTS/BPH.Results: In total, 4,722 patients with a mean age of 66 years were included. Mean nocturia improvements were significantly superior (p ≤ 0.01) with combination therapy than with either monotherapy (adjusted mean change from baseline in IPSS Question 7 score at month 48: combination therapy −0.5, dutasteride −0.4, tamsulosin −0.3). Reduction in nocturia score with combination therapy was significantly (p ≤ 0.01) better than tamsulosin monotherapy across all baseline subgroups tested, except for men with previous 5ARI use. Among those with a baseline IPSS Q7 score ≥2, more patients with combination therapy had a score <2 at month 48 (34 {\%}) compared with dutasteride (30 {\%}, p = 0.018) or tamsulosin (26 {\%}, p < 0.0001).",
keywords = "Combination drug therapy, Dutasteride, Nocturia, Randomised controlled trial, Tamsulosin",
author = "Matthias Oelke and Claus Roehrborn and Carlos D’Ancona and Wilson, {Timothy H.} and Ramiro Castro and Michael Manyak",
year = "2014",
doi = "10.1007/s00345-014-1296-3",
language = "English (US)",
volume = "32",
pages = "1133--1140",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Nocturia improvement in the combination of Avodart® and tamsulosin (CombAT) study

AU - Oelke, Matthias

AU - Roehrborn, Claus

AU - D’Ancona, Carlos

AU - Wilson, Timothy H.

AU - Castro, Ramiro

AU - Manyak, Michael

PY - 2014

Y1 - 2014

N2 - Purpose: The purpose of the study was to assess the impact of dutasteride plus tamsulosin combination therapy, compared with dutasteride or tamsulosin monotherapy, on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) using data from the 4-year CombAT study.Methods: Nocturia was assessed using Question 7 of the International Prostate Symptom Score questionnaire. Efficacy measures included as follows: mean change in nocturia at 3-month intervals up to 48 months; proportion of patients with improvement/worsening in nocturia; nocturnal voiding frequency at baseline and study end, overall and by baseline subgroups; and nocturnal voiding frequency <2 at study end in patients with a baseline score ≥2.Conclusions: Combination therapy provided greater improvements and less worsening of nocturia compared with both dutasteride and tamsulosin monotherapies. These analyses are the first to show greater improvement with a 5ARI/α-blocker combination versus either agent alone for the management of nocturia in patients with LUTS/BPH.Results: In total, 4,722 patients with a mean age of 66 years were included. Mean nocturia improvements were significantly superior (p ≤ 0.01) with combination therapy than with either monotherapy (adjusted mean change from baseline in IPSS Question 7 score at month 48: combination therapy −0.5, dutasteride −0.4, tamsulosin −0.3). Reduction in nocturia score with combination therapy was significantly (p ≤ 0.01) better than tamsulosin monotherapy across all baseline subgroups tested, except for men with previous 5ARI use. Among those with a baseline IPSS Q7 score ≥2, more patients with combination therapy had a score <2 at month 48 (34 %) compared with dutasteride (30 %, p = 0.018) or tamsulosin (26 %, p < 0.0001).

AB - Purpose: The purpose of the study was to assess the impact of dutasteride plus tamsulosin combination therapy, compared with dutasteride or tamsulosin monotherapy, on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) using data from the 4-year CombAT study.Methods: Nocturia was assessed using Question 7 of the International Prostate Symptom Score questionnaire. Efficacy measures included as follows: mean change in nocturia at 3-month intervals up to 48 months; proportion of patients with improvement/worsening in nocturia; nocturnal voiding frequency at baseline and study end, overall and by baseline subgroups; and nocturnal voiding frequency <2 at study end in patients with a baseline score ≥2.Conclusions: Combination therapy provided greater improvements and less worsening of nocturia compared with both dutasteride and tamsulosin monotherapies. These analyses are the first to show greater improvement with a 5ARI/α-blocker combination versus either agent alone for the management of nocturia in patients with LUTS/BPH.Results: In total, 4,722 patients with a mean age of 66 years were included. Mean nocturia improvements were significantly superior (p ≤ 0.01) with combination therapy than with either monotherapy (adjusted mean change from baseline in IPSS Question 7 score at month 48: combination therapy −0.5, dutasteride −0.4, tamsulosin −0.3). Reduction in nocturia score with combination therapy was significantly (p ≤ 0.01) better than tamsulosin monotherapy across all baseline subgroups tested, except for men with previous 5ARI use. Among those with a baseline IPSS Q7 score ≥2, more patients with combination therapy had a score <2 at month 48 (34 %) compared with dutasteride (30 %, p = 0.018) or tamsulosin (26 %, p < 0.0001).

KW - Combination drug therapy

KW - Dutasteride

KW - Nocturia

KW - Randomised controlled trial

KW - Tamsulosin

UR - http://www.scopus.com/inward/record.url?scp=84939879800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939879800&partnerID=8YFLogxK

U2 - 10.1007/s00345-014-1296-3

DO - 10.1007/s00345-014-1296-3

M3 - Article

C2 - 24804842

AN - SCOPUS:84939879800

VL - 32

SP - 1133

EP - 1140

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 5

ER -